ADMA Biologics, Inc. operates in the healthcare sector, within the biotechnology industry, focusing on the development, manufacturing and commercialization of human plasma–derived therapies.

Headquartered in Ramsey, New Jersey, the company specializes in immunoglobulin products used to treat patients with immune deficiencies and other conditions requiring antibody replacement therapy.

ADMA’s vertically integrated model spans the collection of human plasma through to the manufacturing and distribution of specialized biopharmaceutical products.

Its main areas of activity include:

• Development and production of plasma-derived immunoglobulin therapies.
• Collection of human plasma through company-operated plasma centers.
• Manufacturing and purification of biological products used in immune-related treatments.
• Distribution of therapies to hospitals, infusion centers and specialty pharmacies.

The company’s commercial portfolio includes products such as BIVIGAM® and ASCENIV®, which are used in the treatment of primary immunodeficiency diseases and other immune-related conditions.

ADMA primarily serves the United States market, supplying healthcare providers through specialized pharmaceutical distribution networks.

Industry dynamics are influenced by factors such as growing demand for immunoglobulin therapies, regulatory requirements for biologics, plasma supply availability and competition from global plasma-therapy manufacturers.

Shares of ADMA Biologics, Inc. trade on the Nasdaq under the ticker ADMA.

History and Development

ADMA Biologics, Inc. was founded in 2004 with the objective of developing plasma-derived therapies for patients with primary immunodeficiency and other immune-related conditions.

During its early years, the company focused on clinical research and the development of immunoglobulin therapies, conducting laboratory studies and clinical trials in accordance with regulatory standards.

As its product candidates progressed through development and received regulatory approvals, the company expanded its manufacturing and commercial operations.

Throughout the following years, ADMA strengthened its vertically integrated model by acquiring manufacturing assets and expanding its network of plasma-collection centers.

Over time, the company transitioned from a research-focused organization into a commercial biopharmaceutical manufacturer specializing in immunoglobulin products.

In recent years, ADMA Biologics has continued investing in production capacity, plasma collection infrastructure and manufacturing technologies to support increasing demand for immune-therapy treatments in the United States.